embecta | Sustainability Performance
Specializes in medical devices, particularly for diabetes care. Offers solutions to support the treatment and management of chronic conditions with a focus on reliability and patient outcomes.
1924
United States
1,001 - 5,000 employees
Medical Device
$1B - 10B in revenue
$25M - 100M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#7852
Overallⓘ#1796
in United Statesⓘ#125
in Medical DeviceⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Energy consumption
Critical
Controversy level
- Embecta (BD diabetes spinoff) faces inherited product liability exposure from Becton Dickinson's legacy diabetes care portfolio including insulin pen safety class actions, plus sustained pricing scrutiny from US state Medicaid agencies over insulin pen needle pricing.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.